Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Amylyx Pharmaceuticals Inc

Healthcare US AMLX

13.2USD
-0.09(0.68%)

Last update at 2026-06-03T20:00:00Z

Day Range

13.0113.53
LowHigh

52 Week Range

4.2018.61
LowHigh

Fundamentals

  • Previous Close 13.29
  • Market Cap1942.13M
  • Volume1025656
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-152.76600M
  • Revenue TTM-0.66500M
  • Revenue Per Share TTM-0.008
  • Gross Profit TTM -90.40400M
  • Diluted EPS TTM-1.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -144.68900M -302.13600M 54.30M -197.60100M -87.93100M
Minority interest - - - - -
Net income -144.73500M -301.74300M 49.27M -198.37500M -87.87900M
Selling general administrative 62.89M 111.63M 178.86M 127.13M 38.93M
Selling and marketing expenses - 2.70M 9.50M - -
Gross profit -0.52500M 45.22M 355.35M 19.24M 0.28M
Reconciled depreciation 0.53M 0.90M 1.09M 0.49M 0.05M
Ebit -144.68900M -291.88000M 38.80M -201.82800M -82.74000M
Ebitda -144.16400M -290.97600M 39.89M -201.34100M -82.68800M
Depreciation and amortization 0.53M 0.90M 1.09M 0.49M 0.05M
Non operating income net other - - - 3.74M -
Operating income -153.29100M -314.73100M 38.80M -201.34100M -82.68800M
Other operating expenses 153.29M 402.10M 341.98M 223.57M 82.69M
Interest expense - - - 4.29M 0.04M
Tax provision 0.05M -0.39300M 5.03M 0.77M -
Interest income 9.30M 13.81M 16.16M 4.29M 0.04M
Net interest income 9.30M 13.81M 16.16M 4.29M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M -0.39300M 5.03M 0.77M -0.05200M
Total revenue 0.00000M 87.37M 380.79M 22.23M 0.28M
Total operating expenses 152.77M 359.95M 316.54M 220.58M 82.69M
Cost of revenue 0.53M 42.16M 25.44M 2.99M -
Total other income expense net 8.60M 12.60M 15.49M 3.74M -5.24300M
Discontinued operations - - - - -
Net income from continuing ops -144.73500M -301.74300M 49.27M -198.37500M -87.93100M
Net income applicable to common shares - - - -198.37500M -87.93100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 332.64M 193.63M 517.45M 391.45M 105.61M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.60M 12.48M 14.93M 10.11M 8.83M
Total liab 27.39M 28.87M 84.02M 50.85M 256.78M
Total stockholder equity 305.26M 164.76M 433.43M 340.61M -151.16800M
Deferred long term liab - - - - -
Other current liab 17.91M 23.95M 57.72M -2.04000M 13.02M
Common stock 0.01M 0.00700M 0.00700M 0.00700M 0.00100M
Capital stock 0.01M 0.00700M 0.00700M 0.00700M 0.00100M
Retained earnings -751.42700M -606.69200M -304.94900M -354.22000M -155.84500M
Other liab - - - - 0.04M
Good will - - - - -
Other assets - - - 1.19M 0.19M
Cash 226.65M 77.39M 170.20M 346.94M 96.12M
Cash and equivalents - - - - -
Total current liabilities 22.69M 28.41M 82.04M 46.61M 17.40M
Current deferred revenue - - - - -
Net debt -220.69400M -75.41000M -165.96400M -340.66800M -96.11800M
Short term debt 1.26M 1.52M 2.26M 2.04M -
Short long term debt - - - - -
Short long term debt total 5.96M 1.98M 4.24M 6.28M -
Other stockholder equity 1056.27M 771.54M 220.72M 303.45M -3.00800M
Property plant equipment - - - 2.61M 0.47M
Total current assets 323.67M 189.43M 464.67M 382.13M 101.51M
Long term investments - - - - -
Net tangible assets - - - 340.61M -151.16800M
Short term investments 90.33M 99.11M 201.16M 284.42M 45.93M
Net receivables 0.09M 0.45M 40.05M 15.31M -
Long term debt - - - - -
Inventory - 0.00000M 38.32M 9.77M -
Accounts payable 3.52M 2.94M 22.06M 46.61M 17.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.40M -0.09200M 0.20M -0.08600M 0.00900M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00700M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -354.22000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.48M 1.47M 45.66M 1.19M 3.63M
Deferred long term asset charges - - - - -
Non current assets total 8.97M 4.20M 52.79M 9.32M 4.10M
Capital lease obligations 5.96M 1.98M 4.24M 6.28M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 14.18M 75.65M -157.05200M -236.46200M -46.40600M
Change to liabilities - - - 1.85M 0.67M
Total cashflows from investing activities 14.04M 75.65M 92.05M -238.98800M -46.40600M
Net borrowings - - 0.00000M - 25.90M
Total cash from financing activities 257.03M 0.35M 3.54M 431.79M 158.51M
Change to operating activities - - - 21.58M 3.92M
Net income -144.73500M -301.74300M 49.27M -198.37500M -87.93100M
Change in cash 148.80M -92.08300M 107.67M 12.87M 37.31M
Begin period cash flow 78.84M 170.92M 62.53M 50.38M 13.07M
End period cash flow 227.64M 78.84M 170.20M 63.24M 50.38M
Total cash from operating activities -123.34300M -167.64700M 11.92M -179.87100M -74.79900M
Issuance of capital stock - - 231.55M 432.45M 135.00M
Depreciation 0.53M 0.90M 1.09M 0.49M 0.05M
Other cashflows from investing activities - -36.20300M - - -
Dividends paid - - - - -
Change to inventory 0.00000M -9.25300M -73.12900M -9.76900M -9.76900M
Change to account receivables 0.38M 39.60M -24.74400M -15.30600M -15.30600M
Sale purchase of stock - - -3.31500M 434.64M -
Other cashflows from financing activities -3.36100M -1.78400M -3.31500M -0.65800M 23.77M
Change to netincome - - - 21.71M 8.48M
Capital expenditures 0.14M 0.16M 1.24M 2.53M 0.35M
Change receivables - - - -14.81900M -
Cash flows other operating - - - 21.09M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 12.93M -
Change in working capital -1.08300M -45.83100M -65.66100M -1.64100M 4.59M
Stock based compensation 27.64M 33.04M 37.16M 21.71M 3.14M
Other non cash items -5.69500M 145.99M -9.94000M -2.05600M 5.23M
Free cash flow -123.48100M -167.80400M 10.68M -182.39700M -75.15200M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMLX
Amylyx Pharmaceuticals Inc		 -0.09 0.68% 13.20 - 2.77 0.66 6.37 6446.63 -11.707
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals Inc

55 Cambridge Parkway, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director 1992
Mr. Justin B. Klee Co-Founder, Co-CEO & Director 1991
Mr. James M. Frates M.B.A. Chief Financial Officer 1967
Ms. Margaret M. Olinger M.B.A Global Head of Commercial & Chief Commercial Officer 1965
Mr. Tom Holmes Chief Technical Operations Officer NA
Ms. Gina M. Mazzariello Chief Legal Officer & Gen. Counsel 1971
Ms. Shauna Horvath Head of Global Marketing NA
Ms. Debra L. Canner Global Head of HR & CHRO 1959
Dr. Patrick D. Yeramian M.D., MBA, Ph.D. Global Head of Clinical R&D and Chief Medical Officer 1959
Mr. Chris Aiello Head of Canada & GM NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.